


**Supplemental Figure S1. (A)** Patient plasma fulvestrant levels at day 28 and 84 as measured by LC/MS/MS; **(B)** Patient serum estradiol (E2) levels at baseline, day 28 and 84, measured by fluorescent-immuno-assay and corrected for fulvestrant cross-reactivity.



**Supplemental Figure S2.** Cross-reactivity between fulvestrant and estradiol (E2) fluorescent-immuno-assay.

